ArticleArthritis research & therapy2026
IL-35 enhances IL-10⁺ breg-mediated immunoregulation and attenuates inflammation and fibrosis in systemic sclerosis.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study aimed to explore the role of interleukin-35 (IL-35)-mediated regulatory B cells (Bregs) in modulating inflammation and fibrosis in systemic sclerosis (SSc).
methodsPeripheral blood and skin samples from 132 treatment-naïve SSc patients and 58 healthy controls (HCs) were analyzed for IL-35 levels, B cell subsets, and cytokine profiles. CD19⁺ B cells were stimulated with IL-35 or anti-IL-35 monoclonal antibody (mAbIL-35) and co-cultured with autologous CD3⁺ T cells to evaluate immunoregulatory function. A bleomycin-induced SSc mouse model was used to assess in vivo effects.
resultsSSc patients exhibited elevated plasma IL-35, IL-10, IL-6, and BAFF levels, along with increased CD19⁺ B cells and IL-6⁺ effector B cells. However, IL-35⁺ and IL-10⁺ Bregs were significantly decreased in both blood and skin. IL-10, IL-6, and TGF-β1 mRNA levels were increased in skin lesions. IL-35 and IL-10 levels correlated with lung function, skin scores, and inflammatory markers. In vitro, IL-35 promoted IL-10⁺ Breg expansion and cytokine secretion, and suppressed Th1, Th17, and CD8⁺IFN-γ⁺ T cell responses via an IL-10-dependent mechanism. In vivo, IL-35 alleviated fibrosis and inflammation in bleomycin-treated mice, whereas mAbIL-35 exacerbated it.
conclusionWhile IL-35 is compensatorily elevated in SSc, its endogenous levels are insufficient to curb the disease. However, the therapeutic administration of exogenous IL-35 demonstrates significant potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.